We would love to hear your thoughts about our site and services, please take our survey here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
EC
Let's discuss given FDA approval for breast cancer testing was granted a while back why global sales of the Parsortix machine hasn't taken off any suggestions?
Copy, copy, copy, paste, paste, paste...same old!
You are the one that does not understand. You are childish and spend most of your sad time trying to annoy people.
I believe the main way of finding the efficacy (effectiveness) of a new cancer treatment drug for people with metastasized cancer (cancer that has spread) used to be to examine them, test them and ask them. Also compare this information with the people that were given the placebo.
Molecular analysis Companies like Illumina and Thermo Fisher now enable the testing of DNA fragments that can be found in blood from a simple blood sample. These fragments are naturally shed by every cell in your body, and that includes the cancerous ones. Analysing the cancerous ones is called CtDna analysis (cancerous tumour Dna analysis). Angle Plc have discovered the following. If you do exactly the same test on a circulating tumour cell taken from the same blood sample and compare it to the so called CtDna analysis results you sometimes get a different result that gives even more information about the state of the persons cancer. Important up to date information. Angle hypothesize this gives "critical new information not currently available on how the cancer is progressing and which therapies may be affective". I think any Company embarking on a cancer drug trial involving a metastasized cancer MUST want this vital new information. It is a "no brainer". It would be criminal not to get this vital information when doing a very expensive cancer drug trial. Criminal IMHO.
All IMHO.
EC
Your just copying and pasting the same stuff over and over again!
You actually don't understand half the timevwgat your actually posting!
Should be a massive winner IMHO. From the RNS dated 4th Jan:-
"ANGLE will start using the clinical results announced today to support the offer of sample-to-answer DNA molecular solutions to pharma services customers using the ****combined CTC-DNA and ctDNA analysis"****.
This will give any cancer drug trial Company ALL THE AVAILABLE INFORMATION about any cancer that has
metastasized (spread). I.e. the DNA analysis of the CtDNA in the general blood (fragments of DNA) combined with the DNA analysis of the Circulating tumour cells (cells that detach from a tumour and can spread a cancer). This sort of information is invaluable to understand how a treatment is performing, or not.
All IMHO.
EC
Desperate times call for desperate measures btw when is the cash placement?
In a tweet about ten minutes ago. I'm not sure what that translates into sales but might give the shares a little boost seeing how low and bombed out there are again
The standard molecular profiling of general blood CtDna (available now using Illumina/Thermo Fisher tech) **AND** circulating tumour cells (CTC's) from the the same blood sample ***for comparison***! See their RNS dated 4th January "Breakthrough clinical results". As pointed out in the RNS, these results meant that it would be in Illumina's etc.. interests to promote the Parsortix machine alongside their standard general blood CtDNA analysis machines to get the "FULL PICTURE". That is using the general blood CtDna and circulating tumour cell CtDNA comparison approach.
Note analysis of the CTC's gave additional sometimes actionable information about the cancer. Actionable in that the standard molecular profiling of general blood CtDna sometimes ***FAILED**** to indicate targetable DNA that ***WAS FOUND*** IN THE circulating tumour cells! Thus, an opportunity to treat the cancer with targeted DNA with immunotherapy could be MISSED!!! I believe Angle were/are open to some sort of deal with the likes of Illumina/Thermo Fisher. We will find out soon I suspect.
However, I had failed to realise that for use in cancer drug trials Angle Plc THEMSELVES can offer this service! They already use Illumina kit for blood CtDNA analysis. It said so in the RNS of 4th Jan (see below). Obviously, they have loads of Parsortix machines their lab to obtain the circulating tumour cells and they have the tech to do the comparison as set out in the RNS!! This offering will be groundbreaking IMHO!!
https://www.lse.co.uk/rns/AGL/breakthrough-clinical-results-b0km788ah9aflqm.html
All IMHO.
Of a cancers status ONLY when BOTH are analysed from the same tube of blood. See RNS dated 4th Jan. This has massive implications for the cancer immunotherapy treatment Companies throughout the World. Angle have pioneered this new approach and are likely to be the ONLY Company in the World to offer this service to Companies carrying out cancer drug trials.............. Soon. Massive potential profits. I bet we get info on this with the results that are due any day.
All IMHO.
You know the one entitled "Breakthrough clinical results"? Comparing the standard blood CtDna analysis currently offered by the likes of Illumina/Thermo Fisher to the analysis of the circulating tumour cells (obtained using Angle's Parsortix machine) from the same tube of blood was interesting, surely? The results indicated in some cases if the circulating tumour cells were not also analysed then important information could be MISSED. I think that is rather important. Do you agree? I don't quite see how you could not agree! Have a think about that one.
EC.
Or maybe these are simply existing jobs and they are recruiting to replace leavers.
"ANGLE has established a CTC harvest and analysis service from our UK-based Clinical Laboratory based in Guildford for customers worldwide. In alignment with company priorities, we plan to rapidly expand our services to include molecular profiling of CTCs and ctDNA using digital PCR and NGS to add to our image-based assays."
TwoGood2Die.
If Angle are doing so badly as you appear to want people to believe then why are they advertising for a purchasing assistant and a Warehouse/Stores operator? Don't tell me...... it's a ruse to improve the sp!! LOL!
Https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0138032
Everyone should give it a rest on umpteen quotes on 'research' use of Parsortix what matters is roll out of Parsortix for actual live 'testing'..
All these copy and paste citing research use are pretty meaningless what matters is commercial sales without which no traction and hence growth will occur.
I'm not saying that 'research' quotes arn't helpful but it's drowning out dialogue on AGL's future commercial prospects because if you can't sell any machines you don't have a future commercial strategy.
As mentioned earlier Parsortix is FDA approved for 'testing' breast cancer do why arn't we seeing any global sales growth in this area for Parsortix sales?
Https://biblio.ugent.be/publication/01HVRMR53RQ0R4Z1PFARV8B9XF
I can't download the whole text. The aim of the research appears to have been to establish methods of increasing further the efficiency of parsortix when dealing with certain types of pancreatic cancer. University of Ghent
Https://www.clinicaltrials.gov/study/NCT05648240?term=parsortix&rank=7
Something is brewing?
Perhaps the US show went well and fruited some deals?
Https://scholarshipdb.net/jobs-in-France/Precision-Medicine-Strategies-For-Patients-With-Metastases-Of-Colorectal-Carcinoma-Resistant-To-Treatments-Crcm=uf0D5-L87hGUZAAlkGUTnw.html
Team in France working on precision medicine who mention they use Parsortix
Current sp to have any chance of succeeding IMHO. As you point out with further funding there is no reason why the Parsortix technology could not get FDA clearance for medical use with cancers other than breast thus increasing the available market by something like 90%. I hasten to add the existing Breast cancer market combilned with the enourmous cancer drug trials markets should be easily enough for Angle Plc as it stands. To get a bid Angle need a decent sized pharma Co. to realise the potential here.
All IMHO.
Doesn't look like Astra Zenica are in any hurry to buy AGL at a mere £30m no doubt its the lack of full FDA approval for Parsortix to test the majority of cancers that's the deciding factor here!
Years away from any commercialisation I would suggest.
Gawdhelpus !
According to a Biotech manager in a radio 4 interview a day or two (6AM) and never repeated during the day as far as I am aware said, over the past 20 years very few companies had reached the main market and that Aim was no longer doing the job for which it was intended due to the main markets lack of interest. Another factor was lack of awareness which is certainly true for AGL - I did not see nor heard nor read any mention of AGLs FDA approval in the media. I presume companies do issue a press release when they have some really good news so how are investors to invest when they do not know of its existance.
Trials by using Angle's Parsortix machine to catch the circulating tumour cells for testing. Potentially there may also be a massive market for testing the patients circulating tumour cells to see if they are suitable for the Immunotherapy treatment in the first place.
https://en.wikipedia.org/wiki/PD-1_and_PD-L1_inhibitors
All IMHO.
Yep, just a few posts a month would be healthier as cash dwindles